GENFIT S.A. (GNFT): Price and Financial Metrics


GENFIT S.A. (GNFT): $3.45

-0.21 (-5.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GNFT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GNFT Stock Summary

  • With a price/sales ratio of 24.3, Genfit SA has a higher such ratio than 93.84% of stocks in our set.
  • With a year-over-year growth in debt of -58.19%, Genfit SA's debt growth rate surpasses only 5.84% of about US stocks.
  • As for revenue growth, note that GNFT's revenue has grown -85.95% over the past 12 months; that beats the revenue growth of only 1.25% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Genfit SA are IMOS, NVEC, IPHA, SNGX, and PZG.
  • Visit GNFT's SEC page to see the company's official filings. To visit the company's web site, go to www.genfit.com.

GNFT Stock Price Chart Interactive Chart >

Price chart for GNFT

GNFT Price/Volume Stats

Current price $3.45 52-week high $6.38
Prev. close $3.66 52-week low $3.01
Day low $3.35 Volume 6,927
Day high $3.55 Avg. volume 23,415
50-day MA $3.75 Dividend yield N/A
200-day MA $3.86 Market Cap 171.86M

GENFIT S.A. (GNFT) Company Bio


Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.


GNFT Latest News Stream


Event/Time News Detail
Loading, please wait...

GNFT Latest Social Stream


Loading social stream, please wait...

View Full GNFT Social Stream

Latest GNFT News From Around the Web

Below are the latest news stories about Genfit SA that investors may wish to consider to help them evaluate GNFT as an investment opportunity.

GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021

Lille, France; Cambridge , M A ; February 2 6 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of December 31, 2021 and revenues for 2021 1 .

GlobeNewswire | February 28, 2022

GENFIT: 2022 Financial Calendar

Lille, France; Cambridge, MA; January 24, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its provisional financial calendar for 2022. February 28, 2022: Publication of revenue and cash position at December 31, 2021 April 07, 2022: Publication of Full Year 2021 financial statements The 2020 Universal Registration Document and Annual Financial Report (included in the

Yahoo | January 24, 2022

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille, France; Cambridge, MA; January 21, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2021: 137,012 shares€512 873.86

Yahoo | January 21, 2022

Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 78.9% upside potential for GENFIT S.A. Unsponsored ADR (GNFT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | January 11, 2022

How Much Upside is Left in GENFIT S.A. Unsponsored ADR (GNFT)? Wall Street Analysts Think 60%

The mean of analysts' price targets for GENFIT S.A. Unsponsored ADR (GNFT) points to a 59.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | December 23, 2021

Read More 'GNFT' Stories Here

GNFT Price Returns

1-mo -8.00%
3-mo -13.97%
6-mo N/A
1-year -10.85%
3-year -85.68%
5-year N/A
YTD -31.00%
2021 4.17%
2020 -75.88%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7114 seconds.